Biocept Q4 Revenues Drop 14 Percent

NEW YORK (GenomeWeb) – Biocept reported after the close of the market Thursday that its fourth quarter 2018 revenues dropped 14 percent year over year as both total test volumes and billable tests fell short of the prior-year period.

The liquid biopsy assay company reported total revenues of $859,526 for the three months ended Dec. 31, 2018 compared to $995,226 in the same period last year.